SARS-CoV-2 Seroprevalence in Relation to Timing of Symptoms
Authors:
- Joseph E. EbingerJEJoseph E. Ebinger
- Gregory J. BotwinGBGregory J. Botwin
- Christine M. AlbertCAChristine M. Albert
- Mona AlotaibiMAMona Alotaibi
- Moshe ArditiMAMoshe Arditi
- Anders H. BergABAnders H. Berg
- Aleksandra BinekABAleksandra Binek
- Patrick BottingPBPatrick Botting
- Justyna Fert-BoberJFJustyna Fert-Bober
- Jane C. FigueiredoJFJane C. Figueiredo
- Jonathan D. GreinJGJonathan D. Grein
- Wohaib HasanWHWohaib Hasan
Preprint
Abstract
Of individuals with SARS-CoV-2 IgG antibody testing performed, those who contemporaneously experienced a cluster of Covid-19 relevant symptoms in the 1-2 months preceding the antibody assay were more likely to test positive whereas those who experienced the symptom clustering in the prior 3-6 months were more likely to test negative. These findings suggest that antibodies likely wane over a period of months, particularly in relation to the timing of symptoms.Keywords
This publication has 8 references indexed in Scilit:
- Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19New England Journal of Medicine, 2020
- Covid-19: Study reveals six clusters of symptoms that could be used as a clinical prediction toolBMJ, 2020
- Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in BelgiumJAMA, 2020
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infectionsNature Medicine, 2020
- Seroprevalence of SARS-CoV-2–Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020JAMA, 2020
- Interpreting Diagnostic Tests for SARS-CoV-2JAMA, 2020
- Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence Testing in IdahomedRxiv, 2020
- The human antibody response to influenza A virus infection and vaccinationNature Reviews Immunology, 2019